Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression

• Published in: Clinical lung cancer Vol. 24; no. 3; pp. e117 - e121
• Main Authors: Tran, Misha C., Strohbehn, Garth W., Karrison, Theodore G., Rouhani, Sherin J., Segal, Jeremy P., Shergill, Ardaman, Hoffman, Philip C., Patel, Jyoti D., Garassino, Marina C., Vokes, Everett E., Bestvina, Christine M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2023
• Subjects: Adenocarcinoma of Lung - genetics; Biomarkers; Biomarkers, Tumor; Biopsy; Disease Progression; High-Throughput Nucleotide Sequencing; Humans; Liquid biopsy; Lung cancer; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mutation; Precision medicine; Targeted therapy; Biomarkers; Liquid biopsy; Precision medicine; Targeted therapy; Lung cancer
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2023.01.003

•Liquid biopsy and next-generation sequencing of circulating tumor DNA is increasingly used at the time of diagnosis of non-small cell lung cancer. Its role at the time of progression—and whether it will complement or even supplant tissue biopsy-based methods of identifying targetable resistance mutations in lung adenocarcinoma—remains unclear.•In this brief report, we demonstrate using 138 paired tests that tissue-liquid concordance rates at diagnosis are similar to previously published findings (∼80%), followed by steep decline in concordance at the time of progression (∼40%).•These findings suggest ctDNA or tissue biopsy alone is therefore likely to be insufficient to identify resistance mutations at progression in the majority of patients. We encourage practitioners to pursue both methods of testing to maximize the likelihood of identifying a targetable mutation.